These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1303 related items for PubMed ID: 23103368

  • 1. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P, Liu T, Wang Y, Shao S, Zhang W, Lv Y, Yi J, Wang Z.
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G.
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
    Vincent-Salomon A, Jouve M, Genin P, Fréneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P, Sastre-Garau X.
    Cancer; 2002 Apr 15; 94(8):2169-73. PubMed ID: 12001113
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C, Masuda N, Yoshimura K, Tsuda H, Mano M, Ando M, Tamura K, Fujiwara Y.
    Jpn J Clin Oncol; 2009 Aug 15; 39(8):484-90. PubMed ID: 19477897
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K, Oda M, Ogawa K, Tominaga K, Kaneko Y, Shimizu T, Matsumoto S, Oda M, Kurita Y, Taira Y.
    Jpn J Clin Oncol; 2013 Jan 15; 43(1):55-62. PubMed ID: 23225912
    [Abstract] [Full Text] [Related]

  • 10. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y, Booser DJ, Sneige N.
    Cancer; 2005 May 01; 103(9):1763-9. PubMed ID: 15786420
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.
    Asian Pac J Cancer Prev; 2012 May 01; 13(8):4119-23. PubMed ID: 23098527
    [Abstract] [Full Text] [Related]

  • 14. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.
    Breast; 2014 Aug 01; 23(4):466-72. PubMed ID: 24742606
    [Abstract] [Full Text] [Related]

  • 15. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.
    Am J Surg Pathol; 2010 Apr 01; 34(4):575-81. PubMed ID: 20216378
    [Abstract] [Full Text] [Related]

  • 16. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL, Jamehdor MR, Arber JM.
    Mod Pathol; 2000 Aug 01; 13(8):866-73. PubMed ID: 10955453
    [Abstract] [Full Text] [Related]

  • 17. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.
    Oncology; 2011 Aug 01; 80(3-4):269-77. PubMed ID: 21734419
    [Abstract] [Full Text] [Related]

  • 18. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
    Al-Hilli Z, Hieken TJ, Hoskin TL, Heins CN, Boughey JC.
    J Surg Oncol; 2015 Oct 01; 112(5):453-7. PubMed ID: 26345596
    [Abstract] [Full Text] [Related]

  • 19. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
    Chen HR, Wu YT, Yu QB, Yang YY, Wei YX, Li HY, Wu KN, Kong LQ.
    World J Surg Oncol; 2017 Oct 19; 15(1):189. PubMed ID: 29052527
    [Abstract] [Full Text] [Related]

  • 20. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.
    J Surg Oncol; 2002 May 19; 80(1):4-11. PubMed ID: 11967899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.